What is the appropriate management for a patient with moderate diffuse ileus predominantly involving the colon, with left‑sided constipation, currently passing stool and no nausea?

Management of Moderate Diffuse Ileus with Colonic Predominance

For a patient with moderate diffuse ileus predominantly involving the colon who is currently passing stool and no longer experiencing nausea, conservative management with osmotic laxatives and supportive care is the appropriate approach, avoiding stimulant laxatives which are contraindicated in the setting of ileus.

Initial Conservative Management

Since the patient is showing signs of improvement (passing stool, resolution of nausea), continue supportive measures rather than escalating therapy 1:

• Ensure adequate hydration and electrolyte correction - critical for restoring normal bowel function 2, 3
• Discontinue any medications that impair motility - particularly opioids, anticholinergics, and sedatives if possible 1
• Encourage mobilization when clinically appropriate 3
• Maintain bowel rest or advance diet cautiously based on tolerance 2

Pharmacologic Approach for Persistent Constipation

First-Line: Osmotic Laxatives

Start with osmotic laxatives as they are safe in ileus and do not risk worsening intestinal cramping 1:

• Polyethylene glycol (PEG/macrogols) - preferred agent that sequesters fluid in the bowel without systemic absorption 1
• Lactulose 30-60 mL twice to four times daily - alternative osmotic agent 1, 3
• Magnesium salts - useful for more rapid evacuation but avoid sodium-containing preparations 1

Critical Caveat: Avoid Stimulant Laxatives

Do not use stimulant laxatives (senna, bisacodyl, sodium picosulfate) in the setting of ileus - these agents increase intestinal motility and can cause severe cramping, and are specifically contraindicated in intestinal obstruction 1. The guidelines explicitly state stimulant laxatives "should be avoided in intestinal obstruction" 1.

Second-Line Prokinetic Agents (If No Improvement)

If conservative measures and osmotic laxatives fail after 24-48 hours, consider prokinetic therapy 1:

For Small Bowel Involvement:

• Erythromycin 900 mg/day (divided doses) - motilin agonist effective for small bowel dysmotility, though subject to tachyphylaxis 1
• Azithromycin - may be more effective than erythromycin for small bowel dysmotility 1

For Colonic Predominance:

• Prucalopride - selective 5-HT4 receptor agonist with prokinetic properties, licensed for chronic constipation without cardiac risks 1

For Refractory Cases:

• Neostigmine - parasympathomimetic that enhances gut motility; can be given subcutaneously (0.25 mg four times daily) for ileus or acute colonic pseudo-obstruction 1, 4
  • Monitor for bradycardia with telemetry as this is the primary adverse effect 4
  • Contraindicated in patients with heart block or following bowel resection with primary anastomosis 4
  • Median time to first bowel movement is approximately 29 hours 4

Monitoring and Reassessment

Assess for progression to complicated disease by monitoring for 2, 5, 3:

• Worsening abdominal distension or pain
• Recurrence of vomiting or inability to tolerate oral intake
• Signs of peritonitis or perforation
• Fever or systemic inflammatory response
• Failure to pass stool or flatus for >6 days despite treatment 2

When to Escalate Care

Consider surgical consultation or advanced interventions if 5, 3, 6:

• Mechanical obstruction cannot be excluded
• Development of colonic pseudo-obstruction with cecal diameter >12 cm (risk of perforation)
• Clinical deterioration despite 48-72 hours of conservative management
• Signs of bowel ischemia or perforation develop

Special Considerations

For patients on chronic opioids, if this is contributing to the ileus 1:

• Methylnaltrexone 0.15 mg/kg subcutaneously every other day - peripherally acting opioid antagonist that does not affect analgesia 1, 7
• Naloxegol - oral alternative with similar mechanism 7

Avoid metoclopramide and domperidone for long-term management due to extrapyramidal side effects and QTc prolongation risks, respectively 1.